TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
CAPR

Capricor Therapeutics Inc

Healthcare · Biotechnology

7.20$ +13.5% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Capricor Therapeutics Inc (CAPR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 78.3% of the shares are freely tradable; institutional investors hold 59.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 59.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 9.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 78.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 35.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 58Mio.

Largest Shareholders

Institutions

Institutions CAPR
Name Stake (%) Shares Change (%) Date
BlackRock Inc 7.13 4,145,061 +21.1 06/30/2026
TANG CAPITAL MANAGEMENT LLC 7.05 4,099,900 +20.6 06/30/2026
Suvretta Capital Management, LLC 7.04 4,092,784 +7.2 06/30/2026
State Street Corp 5.84 3,397,150 +55.7 06/30/2026
Vanguard Capital Management, LLC 3.95 2,297,674 +13.3 06/30/2026
The Goldman Sachs Group Inc 2.71 1,578,131 +73.0 06/30/2026
RA Capital Management, LLC 2.59 1,507,844 +0.0 06/30/2026

Funds

Funds CAPR
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 3.08 1,791,172 -1.9 09/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.85 1,655,365 +0.0 09/30/2026
iShares Russell 2000 ETF 2.42 1,407,823 -1.1 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?